Department of Chemistry, The Skaggs Institute for Chemical Biology and the Worm Institute of Research and Medicine (WIRM), USA.
Vaccine. 2012 Oct 19;30(47):6665-70. doi: 10.1016/j.vaccine.2012.08.064. Epub 2012 Sep 7.
Despite being consistently ranked as the leading cause of preventable death in the United States, about 20% of the population continues to smoke. Current smoking cessation therapies offer limited success, show high rates of relapse, and have potentially dangerous side effects, consequently emphasizing the need for alternative therapies. Immunopharmacotherapy aims to use highly specific antibodies to sequester nicotine in the bloodstream thus blunting passage into the brain and minimizing positive reinforcing effects. A successful vaccination strategy is dependent upon the appropriate hapten design, carrier protein and adjuvant which affect both the magnitude and affinity of the immune response elicited. Our laboratory previously demonstrated the use of molecular constraint as a means to increase the intrinsic immunogenicity and antigenicity of a nicotine vaccine. The present study expands upon those initial results and explores the protective effects of vaccination with both constrained hapten CNI and its unconstrained counterpart NIC. Our results demonstrate how immunization with CNI-KLH produces large amounts of moderate affinity anti-nicotine antibodies even when formulated with ALUM adjuvant, making it particularly relevant for human use. In contrast, vaccination with NIC-KLH produced moderate amounts of high affinity anti-nicotine antibodies. These differential responses proved critical in offering protecting effects. Vaccination with CNI, but not NIC, resulted in an increase of self-administration responding on a progressive ratio schedule using a high nicotine dose (0.03 mg/kg/infusion; ≈ 2 cigarettes in human) as compared to KLH-controls. Furthermore, vaccination with CNI was able to antagonize the analgesic effects of a heavy bolus dose of nicotine (0.35 mg/kg). These results support our hypothesis that molecular constraint can be advantageously utilized to increase the immunogenicity of a nicotine vaccine. Furthermore in correlating the behavioral effects with the differential responses elicited, we shed light on the distinct roles of antibody concentration and affinity.
尽管吸烟一直被认为是美国可预防死亡的主要原因,但仍有大约 20%的人口继续吸烟。目前的戒烟疗法成功率有限,复发率高,且可能有危险的副作用,因此强调需要替代疗法。免疫药理学旨在使用高度特异性的抗体将尼古丁在血液中隔离,从而阻止其进入大脑并最大限度地减少积极的强化作用。成功的疫苗接种策略取决于适当的半抗原设计、载体蛋白和佐剂,这些都影响免疫反应的幅度和亲和力。我们的实验室之前证明了使用分子约束作为增加尼古丁疫苗固有免疫原性和抗原性的一种方法。本研究扩展了这些初步结果,并探讨了用约束半抗原 CNI 和其非约束对应物 NIC 进行疫苗接种的保护作用。我们的结果表明,即使与 ALUM 佐剂一起配制,用 CNI-KLH 进行免疫接种也会产生大量中等亲和力的抗尼古丁抗体,这使其特别适用于人类使用。相比之下,用 NIC-KLH 进行疫苗接种会产生中等量的高亲和力抗尼古丁抗体。这些差异反应在提供保护作用方面至关重要。与 KLH 对照组相比,用 CNI 而非 NIC 进行疫苗接种会导致在使用高尼古丁剂量(0.03 mg/kg/输注;相当于人类 2 支香烟)的递增比例方案中自我给药反应增加。此外,用 CNI 进行疫苗接种能够拮抗大剂量尼古丁(0.35 mg/kg)的镇痛作用。这些结果支持我们的假设,即分子约束可以被有利地利用来增加尼古丁疫苗的免疫原性。此外,在将行为效应与引起的差异反应相关联时,我们阐明了抗体浓度和亲和力的不同作用。